HK1094950A1 - Method of treating hemolytic disease - Google Patents

Method of treating hemolytic disease

Info

Publication number
HK1094950A1
HK1094950A1 HK07102472.6A HK07102472A HK1094950A1 HK 1094950 A1 HK1094950 A1 HK 1094950A1 HK 07102472 A HK07102472 A HK 07102472A HK 1094950 A1 HK1094950 A1 HK 1094950A1
Authority
HK
Hong Kong
Prior art keywords
hemolytic disease
treating hemolytic
treating
disease
hemolytic
Prior art date
Application number
HK07102472.6A
Other languages
English (en)
Inventor
Leonard Bell
Russell P Rother
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34808492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1094950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of HK1094950A1 publication Critical patent/HK1094950A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK07102472.6A 2004-02-03 2007-03-06 Method of treating hemolytic disease HK1094950A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/771,552 US20050169921A1 (en) 2004-02-03 2004-02-03 Method of treating hemolytic disease
PCT/US2005/003225 WO2005074607A2 (en) 2004-02-03 2005-02-03 Method of treating hemolytic disease

Publications (1)

Publication Number Publication Date
HK1094950A1 true HK1094950A1 (en) 2007-04-20

Family

ID=34808492

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102472.6A HK1094950A1 (en) 2004-02-03 2007-03-06 Method of treating hemolytic disease

Country Status (17)

Country Link
US (5) US20050169921A1 (sl)
EP (7) EP2522361A1 (sl)
JP (5) JP2007520494A (sl)
KR (1) KR101197799B1 (sl)
CN (4) CN103977403A (sl)
AU (1) AU2005209854B2 (sl)
CA (1) CA2554632A1 (sl)
CY (1) CY1113190T1 (sl)
DK (1) DK1720571T3 (sl)
ES (1) ES2389093T3 (sl)
HK (1) HK1094950A1 (sl)
IL (2) IL177003A0 (sl)
NZ (1) NZ549328A (sl)
PL (1) PL1720571T3 (sl)
PT (1) PT1720571E (sl)
SI (1) SI1720571T1 (sl)
WO (1) WO2005074607A2 (sl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US20040115194A1 (en) * 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20090028850A1 (en) * 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006107708A1 (en) * 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin
KR20170002684A (ko) * 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
RS53864B1 (en) * 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. EXTENDING ALOGRAPHIC SURVIVAL BY INHIBITING COMPLEMENT ACTIVITIES
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
PE20121034A1 (es) * 2006-11-02 2012-08-25 Genentech Inc Anticuerpos anti-factor d humanizados
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2815766B1 (en) 2008-08-05 2017-07-05 Novartis AG Compositions and methods for antibodies targeting complement protein C5
PT2894165T (pt) * 2008-11-10 2023-03-17 Alexion Pharma Inc Métodos e composições para o tratamento de distúrbios associados ao complemento
CN106390117A (zh) * 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
SA111320266B1 (ar) * 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
AU2015230852B2 (en) * 2011-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2694108B1 (en) * 2011-04-08 2018-06-06 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
AU2012356170B2 (en) 2011-12-21 2016-06-16 Novartis Ag Compositions and methods for antibodies targeting Factor P
EA201400950A1 (ru) * 2012-03-16 2014-12-30 Алексион Фармасьютикалс, Инк. Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента
RU2018114903A (ru) * 2012-04-06 2019-03-04 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
ES2768648T3 (es) 2013-03-29 2020-06-23 Alexion Pharma Inc Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
KR101834469B1 (ko) 2013-08-07 2018-03-06 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
JP2016539919A (ja) 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
EP3277715A2 (en) * 2015-03-31 2018-02-07 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
IL309975A (en) 2016-06-14 2024-03-01 Regeneron Pharma Antibodies against C5 and their uses
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
KR20230043247A (ko) 2017-01-31 2023-03-30 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
CN111630065A (zh) 2017-12-13 2020-09-04 瑞泽恩制药公司 抗c5抗体组合及其用途
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN112512656A (zh) 2018-05-30 2021-03-16 加利福尼亚大学董事会 用于组织和细胞聚集体解离及单细胞富集的微流体过滤装置及方法
EP3829628B1 (en) 2018-08-01 2024-05-15 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
WO2021019036A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
CR20220040A (es) 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5650825A (en) * 1995-03-31 1997-07-22 Matsushita Electric Corporation Of America Method and apparatus for sending private data instead of stuffing bits in an MPEG bit stream
DE19826743A1 (de) * 1998-06-16 1999-12-23 Bayer Ag Verfahren zur Herstellung von geträgerten Polymerisationskatalysatorsystemen und Verwendung dieser zur Homo- und Copolymerisation ungesättigter Monomere
ATE414720T1 (de) * 2000-12-05 2008-12-15 Alexion Pharma Inc Rationell entworfene antikörper
WO2003081206A2 (en) * 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
KR101197799B9 (ko) 2024-02-08
EP1720571A4 (en) 2008-11-19
CN103977403A (zh) 2014-08-13
US20110086040A1 (en) 2011-04-14
EP2522363A1 (en) 2012-11-14
JP2007520494A (ja) 2007-07-26
JP2015083611A (ja) 2015-04-30
CN103977402A (zh) 2014-08-13
KR101197799B1 (ko) 2012-11-05
ES2389093T3 (es) 2012-10-23
EP2522362A1 (en) 2012-11-14
JP2011126917A (ja) 2011-06-30
EP2910253A1 (en) 2015-08-26
AU2005209854B2 (en) 2011-01-20
CA2554632A1 (en) 2005-08-18
PL1720571T3 (pl) 2012-11-30
CN103446584A (zh) 2013-12-18
EP1720571B9 (en) 2012-10-24
NZ549328A (en) 2010-12-24
EP2520311A3 (en) 2012-11-14
EP2522361A1 (en) 2012-11-14
EP2522364A1 (en) 2012-11-14
EP1720571B1 (en) 2012-06-13
WO2005074607A2 (en) 2005-08-18
EP2520311A2 (en) 2012-11-07
US20100068202A1 (en) 2010-03-18
DK1720571T3 (da) 2012-09-03
JP2013213044A (ja) 2013-10-17
PT1720571E (pt) 2012-08-29
JP5873047B2 (ja) 2016-03-01
AU2005209854A1 (en) 2005-08-18
IL240410A0 (en) 2015-09-24
JP2017057234A (ja) 2017-03-23
CN1938047A (zh) 2007-03-28
KR20070009996A (ko) 2007-01-19
US20050169921A1 (en) 2005-08-04
EP1720571A2 (en) 2006-11-15
US20120308559A1 (en) 2012-12-06
WO2005074607A3 (en) 2006-09-14
SI1720571T1 (sl) 2012-10-30
IL177003A0 (en) 2006-12-10
CY1113190T1 (el) 2016-04-13
US20050191298A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
IL240410A0 (en) Hemolytic disease treatment method
HK1220612A1 (zh) 治療炎症相關疾病的方法
IL175818A0 (en) Method for treating adamts-5- associated disease
ZA201207323B (en) Method of treatment of prophylaxis
EP1838714A4 (en) METHODS OF TREATING PAIN
ZA200508427B (en) Methods for treating interleuking-6 related diseases
EP1635763A4 (en) METHOD FOR TREATING NEURODEEGENERATIVE ILLNESSES
ZA200709024B (en) Method of well treatment and construction
EP1809276A4 (en) PROCESSING PROCESS
GB0306309D0 (en) Method of treatment
GB0302572D0 (en) Method of treatment
EP1600511A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESS
GB0402578D0 (en) Methods of treatment of atherosclerosis
GB0426196D0 (en) Methods of treatment
GB2424579B (en) Method of treating hair
GB0307544D0 (en) Treatment method
GB0327975D0 (en) Methods of treatment
GB0302691D0 (en) Treatment method
GB0408799D0 (en) Method of treating pain
GB0312083D0 (en) Method of treatment
GB0311123D0 (en) Method of treatment
GB0302657D0 (en) Method of treatment
ZA200604552B (en) Method for treating ADAMTS-5-associated disease
GB0406103D0 (en) Treatment method
GB0522330D0 (en) Method of treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160203